BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19237229)

  • 1. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
    Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
    Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
    Gobec S; Brozic P; Rizner TL
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
    Beranič N; Gobec S; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
    Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
    Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
    Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
    Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New enzymatic assay for the AKR1C enzymes.
    Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
    Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
    Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
    Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
    Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
    J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis.
    Zhao Y; Zheng X; Zhang H; Zhai J; Zhang L; Li C; Zeng K; Chen Y; Li Q; Hu X
    Chem Biol Interact; 2015 Oct; 240():310-5. PubMed ID: 26362498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
    Endo S; Hu D; Matsunaga T; Otsuji Y; El-Kabbani O; Kandeel M; Ikari A; Hara A; Kitade Y; Toyooka N
    Bioorg Med Chem; 2014 Oct; 22(19):5220-33. PubMed ID: 25182963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
    Heinrich DM; Flanagan JU; Jamieson SM; Silva S; Rigoreau LJ; Trivier E; Raynham T; Turnbull AP; Denny WA
    Eur J Med Chem; 2013 Apr; 62():738-44. PubMed ID: 23454516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
    Endo S; Matsunaga T; Kanamori A; Otsuji Y; Nagai H; Sundaram K; El-Kabbani O; Toyooka N; Ohta S; Hara A
    J Nat Prod; 2012 Apr; 75(4):716-21. PubMed ID: 22506594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking simulations of steroid substrates into human cytosolic hydroxysteroid dehydrogenases (AKR1C1 and AKR1C2): insights into positional and stereochemical preferences.
    Jin Y; Penning TM
    Steroids; 2006 May; 71(5):380-91. PubMed ID: 16455123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
    Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
    Jamieson SM; Brooke DG; Heinrich D; Atwell GJ; Silva S; Hamilton EJ; Turnbull AP; Rigoreau LJ; Trivier E; Soudy C; Samlal SS; Owen PJ; Schroeder E; Raynham T; Flanagan JU; Denny WA
    J Med Chem; 2012 Sep; 55(17):7746-58. PubMed ID: 22877157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
    Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
    Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
    Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
    Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.